Charles River Laboratories CRL Impairment Charges
Impairment Charges at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by Charles River Laboratories in its filing.
Tagged under the XBRL concept us-gaap:ImpairmentOfLongLivedAssetsHeldForUse.
The official record: Charles River Laboratories’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Charles River Laboratories's impairment charges.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Charles River Laboratories's impairment charges?
- Charles River Laboratories (CRL) reported impairment charges of $15.86M in Q1 2026.
- How has Charles River Laboratories's impairment charges changed year-over-year?
- Charles River Laboratories's impairment charges increased by 50.0% year-over-year, from $10.58M to $15.86M.
- What is the long-term trend for Charles River Laboratories's impairment charges?
- Over 3 years (2021 to 2025), Charles River Laboratories's impairment charges has grown at a 508.3% compound annual growth rate (CAGR), from $733K to $165M.
- What does impairment charges mean?
- A non-cash write-down of an asset's value due to a decline in its worth.
- How do you interpret impairment charges?
- An increase suggests poor past investment decisions or deteriorating market conditions for specific business units.
- How does impairment charges compare across companies?
- Often seen in companies that grow through aggressive M&A; peers may report these periodically following acquisitions.